Stoke Therapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -39.4% | -39.4% | -35.9% |
| FY2022 | -54.7% | -54.7% | -39.5% |
| FY2023 | -65.6% | -65.6% | -45.9% |
| FY2024 | -38.9% | -38.9% | -32.8% |
| FY2025 | -2.0% | -2.0% | -1.6% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -39.4% | -39.4% | -35.9% |
| FY2022 | -54.7% | -54.7% | -39.5% |
| FY2023 | -65.6% | -65.6% | -45.9% |
| FY2024 | -38.9% | -38.9% | -32.8% |
| FY2025 | -2.0% | -2.0% | -1.6% |